SILVER-LAKE/SILAE
8.7.2020 07:02:07 CEST | Business Wire | Press release
Silae, a specialist provider of cloud-based payroll and HR software for the French market, and Silver Lake, a global technology investment firm, today announced that Silver Lake is to acquire 100% of Silae from its founding shareholders, who intend to remain involved in the business.
Jean-Paul Bagou, Michel Delolme, Didier Fléchet, Philippe Marty and Daniel Mayet, co-founders of Silae, said: “As a founder group, we are extremely proud of what Silae has achieved over the past decade. Together with our exceptional and talented employees and partners, we have built a highly successful company and laid a strong foundation for the future by developing a suite of leading SaaS Payroll and HR software products and continuously improving our customer service. As Silae begins an exciting new chapter of product innovation and growth, we are thrilled to partner with Silver Lake, a world-class technology investor with deep software industry expertise and value creation capabilities. This investment marks an acceleration point for our company, employees, customers and partners, as we gain further strength to reinforce our current position in the market while continuing to develop new innovative products and services.”
Christian Lucas, Co-Head of Silver Lake EMEA said: “We want to thank all five founders of Silae for entrusting us with the very special company that they have built over the past decade. We are highly impressed by how, together with employees, they have built Silae into an outstanding and fast-growing company, with an established track record of providing best-in-class SaaS solutions in the payroll and HR segments. Investing in high-growth, innovative, founder-led technology businesses is at the core of Silver Lake’s DNA and it is a privilege to partner with the current team. As the company enters a new phase of value creation, we look forward to continuing working with them and we intend to invest in the company’s continued success to further strengthen its technology platform, as well as its products and services offered to its current and future clients.”
Founded in 2010 and headquartered in Aix-en-Provence, France, Silae is a specialist provider of fully cloud-based Payroll and HR software, offering a range of SaaS solutions and cloud services to simplify and automate complex processes for more than 550,000 businesses in France in close partnership with a wide network of CPAs and HR outsourcing specialists. Silae’s proprietary and highly automated core software platform Silaexpert provides unique scalability to its partner network, enabling substantial efficiency increases along the HR process chain and attracting a rapidly growing number of customers and partners. Silae has established a strong trajectory of growth and profitability increases, more than doubling its revenue and tripling its EBITDA over the past two years. In 2020, Silae is on track to reach a further major milestone on its growth path by becoming the trusted partner for more than 4 million employees in France who will have their payroll slips processed by the company’s solutions.
Silver Lake is planning to invest in Silae and support it in its next phase of development as the company is set to further accelerate its growth, through innovative new products such as its employee engagement solution PaiePilote, as well as to build on its strong technology expertise to extend its product offering while keeping its identity and continuing to provide best-in-class service to its customers. Silver Lake will thereby preserve Silae’s existing operating model, strengthen it further and make its offering even more accessible to customers.
Financial terms of the transaction were not disclosed. The transaction is expected to close in the third quarter subject to regulatory approval.
About Silae
Founded in 2010 and headquartered in Aix-en-Provence, France, Silae is a provider of cloud-based Payroll and HR software, offering a broad range of solutions to more than 550,000 businesses in partnership with its strong network of CPA and HR outsourcing partners. The company’s core SaaS product line Silaexpert enables full automation of complex payroll and HR processes, ensuring full adherence with constantly evolving labour and tax regulations in France and facilitating seamless communication and data exchange between outsourcing partners and customers in a highly collaborative environment. For more information, please visit silaexpert.fr.
About Silver Lake
Silver Lake is a global technology investment firm, with over $40 billion in combined assets under management and committed capital and a team of approximately 100 investment and operating professionals located in Silicon Valley, New York, London and Hong Kong. Silver Lake’s portfolio of investments collectively generates more than $230 billion of revenue annually and employs 370,000 people globally. For more information about Silver Lake and its portfolio, please visit silverlake.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005948/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
